跳至主要内容
临床试验/NCT05448768
NCT05448768
Enrolling By Invitation
不适用

Biomarker-based Prediction of Cognitive Effects and Potential Mechanisms of Theta-burst Stimulation (TBS) in Subjects With Mild Cognitive Impairment (MCI)

Chang Gung Memorial Hospital1 个研究点 分布在 1 个国家目标入组 80 人2022年9月13日

概览

阶段
不适用
干预措施
未指定
疾病 / 适应症
Mild Cognitive Impairment
发起方
Chang Gung Memorial Hospital
入组人数
80
试验地点
1
主要终点
Montreal Cognitive Assessment
状态
Enrolling By Invitation
最后更新
上个月

概览

简要总结

This study aims to examine the effects and potential mechanisms of theta-burst stimulation (TBS) on cognitive function in individuals with mild cognitive impairment (MCI).

详细描述

The investigators apply the NIA-AA criteria to subtype different endophenotypes of biomarker-defined MCI individuals. This is a prospective, open-label clinical trial, and combined functional neuroimaging study of 18F-FDG-PET to further explore the potential mechanisms. A total of 80 MCI patients will be consecutively recruited and be subjected to iTBS for 5 daily interventions per week for two consecutive weeks. Cognitive evaluation will be performed before and immediately after TBS intervention, and 8 weeks after TBS. Data on functional neuroimaging will be also collected before and after TBS protocol.

注册库
clinicaltrials.gov
开始日期
2022年9月13日
结束日期
2027年6月30日
最后更新
上个月
研究类型
Interventional
研究设计
Parallel
性别
All

研究者

发起方
Chang Gung Memorial Hospital
责任方
Sponsor

入排标准

入选标准

  • Subjects aged 50-90 year
  • Subjects meet Petersen's criteria for mild cognitive impairment (Petersen, Smith et al. 1999)
  • The CDR of MCI patients can be 0-0.5
  • Amyloid PET should ever be performed

排除标准

  • Any subject has a definite diagnosis of epilepsy or history of seizure attack.
  • Current or past history of clinically significant neurological insults affecting brain structure or function like completed stroke, head injury or brain tumor.
  • Any subject has clinically significant or unstable medical diseases including metabolic, renal,liver, lung or cardiovascular disorders including metabolic, renal, liver, lung or cardiovascular disorders.
  • Any subject has current alcohol or other substances abuse and/ or dependence within the recent one year, or prolonged history of major psychiatric disorder like schizophrenia,bipolar disorder, and previously prolonged substances abuse.
  • Any females who is pregnant or lactating.
  • General MRI, TMS and/or PET exclusion criteria including subjects who had received brain aneurysm surgery, or implanted pacemaker, mechanical valves, cochlear implant or other metal devices/ objects that are not MR compatible in the body.
  • Withdrawal criteria
  • Complications onset after intervention that affect efficacy and safety judgments.
  • New onset or progression of disease that may affect outcomes.
  • Use of other therapies or drugs during the intervention period to change cognitive functions.

结局指标

主要结局

Montreal Cognitive Assessment

时间窗: Baseline and immediately after 2 weeks of TBS and 8-week follow-up after TBS

Change from baseline Montreal Cognitive Assessment total scores immediately after TBS intervention

Mini-Mental State Examination ( MMSE )

时间窗: Baseline and immediately after 2 weeks of TBS and 8-week follow-up after TBS

Change from baseline Mini-Mental State Examination total scores immediately after TBS intervention

次要结局

  • The standard uptake values changes of FDG-PET(Before and immediately after TBS intervention)

研究点 (1)

Loading locations...

相似试验